BRWA
ORMP icon

B. Riley Wealth Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

B. Riley Wealth Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,883
Closed -$280K – 1452
2021
Q2 		$280K Buy
20,883
+1,378
+7% +$15.8K 0.01% 1057
2021
Q1 		$199K Buy
+19,505
New +$160K 0.01% 1197
2015
Q1 		– Sell
-500
Closed -$2 – 1535
2014
Q4 		$2 Buy
+500
New +$3.29K ﹤0.01% 3418
2014
Q3 		– Sell
-500
Closed -$4.81K – 1496
2014
Q2 		$4.81K Buy
+500
New +$5.11K ﹤0.01% 2056

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
JC
Jetstream Capital Brentwood, Tennessee $1.37M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

B. Riley Wealth Advisors's ORMP Position: Q3 2021 in Review

B. Riley Wealth Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q3 2021, closing a stake of 20,883 shares — an estimated $280K sold.

B. Riley Wealth Advisors first reported a position in ORMP in Q2 2014 and held it in 4 quarters. The position peaked at $280K in Q2 2021. 93 funds tracked by Wall St. Rank hold ORMP as of Q3 2021.

  • B. Riley Wealth Advisors reported no remaining Oramed Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 20,883 Oramed Pharmaceuticals shares in Q3 2021, an estimated $280K.
  • B. Riley Wealth Advisors first reported a position in Oramed Pharmaceuticals in Q2 2014 and held it in 4 quarters.
  • B. Riley Wealth Advisors's Oramed Pharmaceuticals position peaked at $280K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2021.

Based on B. Riley Wealth Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.